Fincchta
Fincchta
Publications
Hospital-based HTAs are based on mini-HTA proposals conducted within the wellbeing services counties. These decisions have been provided in English from 2023 onwards (the topic only, the publication in pdf format can be requested by e-mail). Most mini-HTA decisions in Finland deal with medicines, a smaller proportion with devices or methods.
Please note that on a mobile device, you may need to scroll horizontally to view all columns of the updated assessment list.
For more information on a specific mini-HTA, please contact johanna.liinamaa(at)pohde.fi or the chief assessment physician of the respective wellbeing service county
The list includes reports in which FinCCHTA has acted either as the main implementer or as a co-implementer.
- Fimea’s assessment reports
Fimea produces and compiles assessments of the therapeutic and economic value of medicines. The goal of these assessments is to compare different drug treatments intended for the same disease. - Nursing recommendations
The national recommendations developed by the Nursing Research Foundation (Hotus) aim to ensure humane, timely, and effective patient care.
- Current Care Guidelines
The Finnish Medical Society Duodecim and specialist physician associations develop independent national guidelines to support clinical decision-making.
- PALKO’s recommendations and statements
The Council for Choices in Health Care in Finland (PALKO) provides recommendations on which procedures, examinations, treatment, and rehabilitation methods are included or excluded from publicly funded healthcare services in Finland.
- Cochrane Library
The database contains reviews produced by the international Cochrane research network (Cochrane Collaboration). Summaries are freely accessible, but a license is required to access the full reviews (e.g., through medical libraries or Terveysportti). - International HTA Database
The database contains basic information on assessment reports and ongoing HTA projects from over 120 HTA organizations. The publication language varies, but information on at least the latest reviews and projects is also available in English.
| Date | ERVA | Active Substance /Method | Intended use | Recommendation |
|---|---|---|---|---|
| 3/2026 | HUS | Optilume | Optilume drug-eluting balloon dilator for the treatment of urethral strictures | Yes |
| 3/2026 | TAYS | Blinatumomab | For the treatment of acute lymphoblastic leukemia (ALL) in patients under 18 years of age | Yes |
| 5/2026 | HUS | Long-read genome sequencer | The sequencer required to produce long sequences identifies genetic changes that current methods based on short-read sequencing cannot reliably detect. | Yes |
| Date | YTA | Active Substance /Method | Intended use | Recommendation |
|---|---|---|---|---|
| 1/2023 | HUS | Pembrolizumab (Keytruda) | Neoadjuvant therapy in the treatment of triple-negative breast cancer | Yes |
| 1/2023 | HUS | Sacituzumab govitecan (Trodelvy®) | Advanced triple-negative breast cancer | Yes |
| 1/2023 | HUS | Dabrafenib (Tafinlar) + Trametinib (Mekinist) -yhdistelmähoito | Treatment of advanced BRAF V600 mutation-positive non-small cell lung cancer in adult patients | No |
| 1/2023 | TAYS | Pembrolizumab (Keytruda®) | Locally advanced or metastatic triple-negative breast cancer | Yes |
| 1/2023 | TAYS | Sacituzumab govitecan (Trodelvy®) | Advanced triple-negative breast cancer | Yes |
| 1/2023 | TAYS | Nivolumab (Opdivo) | Adjuvant treatment of esophageal cancer or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and surgery | Yes |
| 3/2023 | HUS | Nivolumab (Opdivo) + oxaliplatin-capecitabine (XELOX) -combination therapy | First-line treatment for adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma with a tumor PD-L1 expression CPS score of at least 5 | Yes |
| 3/2023 | HUS | Nivolumab (Opdivo) + fluoropyrimidine- and platinum-based chemotherapy combination therapy | First-line treatment for adults with unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression of at least 1% | Yes |
| 3/2023 | HUS | Pembrolizumab (Keytruda) | As adjuvant therapy for patients with stage 2C melanoma (indication extension) | Yes |
| 3/2023 | OYS | Renal denervation | Treatment of resistant hypertension | Yes |
| 3/2023 | HUS | Aptima HPV Genotype Reflex Test | Detects HPV 16 and HPV 18/45 virus types separately | Yes |
| 3/2023 | TAYS | Esketamine | Treatment-resistant depression | No |
| 3/2023 | TYKS | Nivolumab (Obdivo®) | Nivolumab (Opdivo®) – monotherapy as adjuvant treatment for adult patients with muscle-invasive urothelial carcinoma | Yes |
| 4/2023 | HUS | Trastuzumab-deruxtecan (Enhertu®) | Advanced HER2-positive breast cancer second-line treatment | Yes |
| 4/2023 | HUS | Cabozantinib (Cabometyx®) | Third-line treatment for patients with treatment-resistant osteosarcoma or Ewing’s sarcoma | Yes |
| 4/2023 | HUS | Ruxolitinib (Jakavi®) | Treatment of severe steroid-resistant graft-versus-host disease in children | Yes |
| 4/2023 | HUS | Mepolizumab (Nucala®) | Adjunctive treatment for adult patients with hypereosinophilic syndrome (HES) when disease control is inadequate and no non-hematologic secondary cause has been identified. | Yes |
| 4/2023 | HUS | Mepolizumab (Nucala®) | Adjunctive treatment for patients with relapsing-remitting or treatment-resistant eosinophilic granulomatosis with polyangiitis (EGPA). | Yes |
| 4/2023 | HUS | Imlifidase (Idefirix) | Desensitization therapy for highly sensitized adult kidney transplant patients with a positive crossmatch against deceased donor tissues. | Yes |
| 5/2023 | HUS | Tebentafusp | Treatment of choroidal melanoma | Yes |
| 5/2023 | TAYS | Trastuzumab-deruxtecan (Enhertu®) | Metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma, second-line treatment | No |
| 5/2023 | TYKS | Amivantamab (Rybrevant) | Non-small cell lung cancer | No |
| 8/2023 | TAYS | Spesolimab | Monotherapy for the treatment of flares in generalized pustular psoriasis | No |
| 8/2023 | TAYS | Luspatersept | Red blood cell transfusion-dependent anemia associated with myelodysplastic syndrome | No |
| 8/2023 | TYKS | Axicaptagene ciloleusel (Yescarta) | CAR T-cell therapy: axicabtagene ciloleucel (Yescarta®) indication extension for the treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). | Yes |
| 8/2023 | OYS | Nivolumab | Neoadjuvant treatment for resectable NSCLC (non-small cell lung cancer) | Yes |
| 9/2023 | HUS | Peginterferon alfa-2a (Pegasys®) | Pegylated interferon alfa-2a (Pegasys®) for the treatment of pediatric myeloproliferative disease (polycythemia vera and essential thrombocythemia). | Yes |
| 9/2023 | HUS | Axicaptagene ciloleusel (Yescarta®) | Treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) when the disease has relapsed within 12 months of completing first-line therapy. | Yes |
| 10/2023 | OYS | Atezolizumab | 50% and whose disease has not progressed after platinum-based chemotherapy.>As adjuvant therapy after complete tumor resection for adults with stage II–IIIa NSCLC diagnosis, whose tumors have PD-L1 expression >50% and whose disease has not progressed after platinum-based chemotherapy. | Yes |
| 11/2023 | HUS | Sasituzumab govitecan (Trodelvy®) | For well-functioning patients (WHO 0-1) with metastatic or locally advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have previously received 2–4 lines of chemotherapy (including a taxane as the first-line treatment, at least one hormone therapy, and one CDK4/6 inhibitor treatment line). | Yes |
| 11/2023 | HUS | Trastuzumab deruxtecan (Enhertu) | For well-functioning patients (WHO 0-1) with metastatic hormone receptor-positive or -negative breast cancer who have previously received 1–2 lines of chemotherapy and whose tumor shows low-level HER2 positivity based on immunohistochemical analysis (HER2 1+ or 2+ and ISH-negative = HER2-low). | Yes |
| 11/2023 | HUS | Symani Surgical System – microanastomosis robot | Patients undergoing reconstructive microsurgery where a microsurgical vascular, nerve, or lymphatic anastomosis is planned, particularly those with anastomosed structures less than 2 mm in diameter. | No |
| 11/2023 | HUS | Mepolizumab and benralizumab | IL-5 (mepolizumab) and IL-5R (benralizumab) antibodies for eosinophilic pneumonia or bronchopulmonary aspergillosis | Yes |
| 1/2024 | HUS | Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine | First-line treatment for advanced urothelial carcinoma | Yes |
| 1/2024 | TAYS | Atezolizumab | Adjuvant treatment for non-small cell lung cancer (NSCLC) when PD-L1 expression is at least 50% | Yes |
| 1/2024 | TAYS | Amoxicillin – clavulanic acid / Xilmac | Antibiotic prophylaxis, infection treatment | Yes |
| 1/2024 | TAYS | Nivolumab | Combination therapy with platinum-based chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) in adults whose tumor PD-L1 expression is at least 1%. | Yes |
| 1/2024 | HUS | Dostarlimab in combination therapy with carboplatin and paclitaxel | For the treatment of primary advanced or recurrent dMMR/MSI-H endometrial cancer. | Yes |
| 1/2024 | TYKS | Pembrolizumab (Keytruda) | Pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-based chemotherapy as first-line treatment for HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults. | Yes |
| 1/2024 | TYKS | Pembrolizumab (Keytruda) | Pembrolizumab (Keytruda) in combination with fluoropyrimidine-, platinum-based chemotherapy, and trastuzumab for locally advanced or metastatic HER2-positive gastroesophageal junction adenocarcinoma. | Yes |
| 2/2024 | HUS | Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) therapy for pancreatic tumors | Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) therapy for pancreatic tumors | Yes |
| 4/2024 | HUS | A-NRP (Abdominal Normothermic Regional Perfusion) in organ transplantation | Abdominal normothermic perfusion in organ transplantation | Yes |
| 4/2024 | HUS | Tisagenlecleusel (Kymriah) | Tisagenlecleucel (Kymriah) for adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more lines of systemic therapy. | Yes |
| 4/2024 | HUS | Pembrolizumab in combination with trastuzumab and fluoropyrimidine-platinum-based combination chemotherapy. | First-line treatment for adults with unresectable, advanced, recurrent, or metastatic HER2-positive gastroesophageal junction adenocarcinoma, with a tumor PD-L1 ligand expression CPS score of at least 1. | Yes |
| 4/2024 | HUS | Tenecteplase (Metalyse®) | As a thrombolytic treatment for acute ischemic stroke. | Yes |
| 5/2024 | HUS | Bulevirtide (Hepcludex®) | In the treatment of D hepatitis. | Yes |
| 5/2024 | HUS | Pembrolizumab as adjuvant therapy for the treatment of radically resected high-risk clear cell renal cell carcinoma. | For the treatment of radically resected high-risk clear cell renal cell carcinoma. | Yes |
| 6/2024 | HUS | Osilodrostat | Osilodrostat for the treatment of severe, life-threatening hypercortisolism. | Yes |
| 6/2024 | HUS | ECMO | ECPR (Extracorporeal Cardiopulmonary Resuscitation) ECMO-assisted resuscitation. | Yes |
| 6/2024 | HUS | Genetic testing | Expansion of the indication for genetic testing in breast cancer patients. | Yes |
| 9/2024 | OYS | Tafasitamab-lenalidomid | Relapsed and treatment-refractory diffuse B-cell lymphoma in patients who are not candidates for autologous stem cell transplantation. | No |
| 10/2024 | HUS | TS-BRCA1/2 mutation testing requirement | TS-BRCA1/2 mutation testing requirement in metastatic castration-resistant prostate cancer (MCRPC). | Yes |
| 10/2024 | KYS | Farisimab | Treatment of retinal vein occlusion. | Yes |
| 11/2024 | HUS | Combination therapy of pembrolizumab and lenvatinib | In anaplastic and poorly differentiated thyroid cancer. | Yes |
| 11/2024 | HUS | Palopegteriparatide | In the treatment of chronic hypoparathyroidism in adults. | Yes |
| 11/2024 | HUS | Upadacitinib | In the treatment of severe, drug-resistant inflammatory bowel disease (IBD) in children (Ulcerative colitis, Crohn’s disease, or undifferentiated IBD). | Yes |
| 11/2024 | HUS | ION robot bronchoscope (Surgical Intuitive) 3 | Patients with imaging or follow-up findings indicating a lung change that requires tissue sample collection for diagnosis and treatment planning. | Yes |
| 12/2024 | HUS | Letermovir | Prevention of cytomegalovirus (CMV) reactivation and virus-induced disease in CMV-seropositive pediatric patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). | Yes |
| 9/2024 | TAYS | Inhaled amikacin (Arikayce) | Refractory pulmonary mycobacterial infection | Yes |
| 9/2024 | HUS | Naldemedine (Rizmoic) | Treatment of opiate constipation | Yes |
| 10/2024 | TAYS | Palopegteriparatide (Yorvipath) | Chronic hypoparathyroidism | No |
| 12/2024 | TAYS | Dextrazocan (Savene) | Cardioprotective drug in conjunction with the use of anthracyclines | Yes |
| 2/2025 | OYS | Nivolumab-ipilimumab | In the treatment of non-small cell lung cancer (PD-L1 < 1% group) | Yes |
| 2/2025 | HUS | Infliximab (s.c.) | In the treatment of pediatric IBD and rheumatoid arthritis – off-label use | Yes |
| 2/2025 | HUS | Pembrolizumab (Keytruda) | Locally advanced stage III-IVA (FIGO 2014) cervical cancer during chemoradiotherapy and as maintenance therapy after chemoradiotherapy | Yes |
| 2/2025 | HUS | EFTR and Ovesco-FTRD | Endoscopic full thickness resection (EFTR): Ovesco Full thickness resection device (Ovesco-FTRD) | Yes |
| 3/2025 | TAYS | Cryoablation | Minimally invasive breast cancer treatment, e.g. in the elderly | Yes |
| 3/2025 | TAYS | Aztreonam-avibactam | Infections caused by multidrug-resistant bacteria | Yes |
| 3/2025 | HUS | Symani Surgical System Microanastomosis Robot (Reassessment) | Reconstructive microsurgery patients | No |
| 3/2025 | HUS | Intravascular laser (The Philips Laser System – Nexcimer) | Opening of blocked calcified coronary arteries and peripheral arteries | Yes |
| 4/2025 | HUS | Everolimus | Everolimus for the treatment of tuberous sclerosis angiomyolipomas in children at risk of complications but not requiring immediate surgery | Yes |
| 4/2025 | KYS | Inhaled amikasin | Inhaled amikacin for MAC infection unresponsive to conventional medical therapy | Yes |
| 5/2025 | TAYS | Exoscope | Microsurgical operations | Yes |
| 5/2025 | HUS | Nivolumab | Nivolumab in combination with AVD chemotherapy in primary stage III-IV classical Hodgkin lymphoma | Yes |
| 5/2025 | HUS | Dostarlimab (in combination with carboplatin and paclitaxel) | Dostarlimab in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent MMRp-type endometrial cancer | Yes |
| 5/2025 | HUS | Brentuximab vedotin | Brentuximab vedotin (BV) in combination with ECADD chemotherapy in primary stage IIB-IV classical high-risk Hodgkin lymphoma | Yes |
| 6/2025 | OYS | Everolimus | Everolimus in the treatment of gastrointestinal neuroendocrine tumors | No |
| 6/2025 | HUS | TA-NRP (ThoracoAbdominal Normothermic Regional Perfusion) | Normothermic perfusion of the thoracic cavity and abdominal region in organ donation | Yes |
| 6/2025 | HUS | Pembrolitsumab | In locally advanced stage III-IVA (FIGO 2014) cervical cancer during chemoradiotherapy and as maintenance therapy after chemoradiotherapy | Yes |
| 6/2025 | HUS | Pembrolizumab in combination with paclitaxel and carboplatin | In advanced or recurrent endometrial cancer (regardless of MMR status) | Yes |
| 6/2025 | KYS | Sorafenib | Maintenance of remission after allogeneic stem cell transplantation in AML patients with FLT3 gene length mutation (FLT3-ITD) | Yes |
| 6/2025 | HUS | Benralitsumab (Fasenra) | As an add-on therapy for adult patients with relapsed or refractory eosinophilic granulomatosis with polyangiitis (EGPA) | Yes |
| 6/2025 | HUS | Pembrolizumab in combination with chemotherapy (carboplatin/cisplatin and pemetrexed) | For first-line treatment of non-epithelial malignant pleural mesothelioma in adults who are ineligible for surgery | Yes |
| 6/2025 | HUS | Nivolumab (Opdivo®) – Ipilimumab (Yervoy®) | Treatment of advanced or unresectable colorectal cancer in adult patients with microsatellite instability (MSI-H) or DNA duplication error repair (dMMR) deficiency who are eligible for combination immuno-oncology therapy | Yes |
| 6/2025 | HUS | Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) therapy | For patients with ABC subtype diffuse large B-cell lymphoma | Yes |
| 8/2025 | HUS | Pembrolizumab in combination with chemotherapy (carboplatin/cisplatin and pemetrexed) | For first-line treatment of non-epithelial malignant pleural mesothelioma in adults who are ineligible for surgery | Yes |
| 8/2025 | TAYS | Spesolimab (Spevigo) | Treatment of generalized pustular psoriasis, exacerbation in adults | Yes |
| 10/2025 | HUS | Trastuzumab-deruxtecan (Enhertu®) | Trastuzumab-deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or esophagogastric junction adenocarcinoma, who have received prior trastuzumab-based therapy. | Yes |
| 11/2025 | HUS | Rbfracture (Radiobotics), BoneView (Gleamer) | Identifying fractures, joint dislocations, and joint effusions from X-ray images using artificial intelligence | Yes |
| 12/2025 | HUS | Dinutuximab beta (Qarziba) | In children with high-risk neuroblastoma | Yes |
| Date | ERVA | Topic | Recommendation |
|---|---|---|---|
| 12/2022 | TAYS | Derivo peripheral embolization device perifeeristen valtimoaneurysmien hoidossa | Yes |
| 12/2022 | KYS | Farisimabi (Vabysmo) silmänpohjan kostean ikärappeuman ja diabeettisen makulaturvotuksen hoidossa | Yes |
| 11/2022 | KYS | Tisagenlekleuseeli (Kymriah) follikulaarisen lymfooman hoidossa | Yes |
| 12/2022 | TYKS | Tisagenlekleuseelim(Kymriah) akuutissa lymfaattisessa leukemiassa lapsilla ja ≤25-vuotiailla nuorilla aikuisilla) | Yes |
| 11/2022 | HUS | AnkerStim-oksipitaalistimulaattori sarjoittaisen pääsäryn hoidossa | Yes |
| 10/2022 | HUS | Rituksimabi MS-taudin hoidossa | Yes |
| 9/2022 | HUS | Basiliksimabi-induktio (Simulect) maksansiirroissa | Yes |
| 9/2022 | TAYS | Tafasitamabi (Minjuvi) yhdistelmänä lenalidomidin kanssa potilaille, joillaon uusiutunut tai hoitoon reagoimaton diffuusi suurisoluinen B‑solulymfooma (DLBCL) ja jotka eivät sovellu autologiseen kantasolusiirtoon (ASCT) | Yes |
| 9/2022 | KYS | Semiplimabi (Libtayo®) monoterapiana ei-pienisoluisen keuhkosyövän ensilinjan hoidossa | Yes |
| 8/2022 | TAYS | The Hot AXIOS Stent and Electrocautery-Enhanced Delivery System haimatulehdusten aiheuttamien retroperitoneaalisten nestekollektioiden dreneerauksessa | Yes |
| 8/2022 | TAYS | Pembrolitsumabi (Keytruda) munuaissolukarsinooman adjuvanttihoitona nefrektomian jälkeen kun uusiutumisriski on suurentunut tai nefrektomian ja metastaattisten leesioiden poiston jälkeen | Yes |
| 7/2022 | TAYS | Eptinetsumabi (Vyepti) vaikean migreenin estohoitona kipupoliklinikan kautta | Yes |
| 6/2022 | KYS | Elosufaasi Alfa (Vimizim®) mukopolysakkaridoosi IVA (MPS IVA, Morquio A syndrooma) hoidossa | Yes |
| 6/2022 | HUS | Siltuksimabi (Sylvant®) Castlemanin taudin hoitoon | Yes |
| 6/2022 | HUS | Adaptiivinen kuvantamisohjattu sädehoito | Yes |
| 6/2022 | HUS | Vyöruusu-rekombinanttirokotteen (Shingrix®) käyttöönotto autologisen kantasolusiirteellä tuetun intensiivihoidon jälkeen | Yes |
| 6/2022 | HUS | Nivolumabi monoterapiana lihakseen tunkeutuvan uroteelikarsinooman (MIUC) liitännäishoitoon aikuisille, joiden kasvainsolujen PD-L1 ilmentymä on ≥ 1 % ja joilla on suuri riski taudin uusiutumiseen lihakseen tunkeutuvan uroteelikarsinooman radikaaliresektion jälkeen | Yes |
| 6/2022 | HUS | Isatuksimabin käyttö aikuispotilailla, joilla on relapsoiva ja refraktorinen multippeli myelooma (MM) ja jotka ovat saaneet vähintään kahta aiempaa hoitoa | Yes |
| 3/2022 | OYS | F18-fluorokoliini PET-TT -kuvantaminen lisäkilpirauhasen adenoomien ja/tai hyperplasian paikantamisessa | Yes |
| 11/2021 | HUS | Älyinsuliinipumpun käyttöönotto lapsipotilailla (advanced hybrid-closed loop, aHCL) | Yes |
| 11/2021 | HUS | Älykkäät kestokäyttöiset insuliinikynät 1 ja 2 tyypin insuliinihoitoisten diabeetikkojen käyttöön (NovoPen6® ja NovoPen® Echo Plus) | Yes |
| 11/2021 | HUS | Dostarlimabi (Jemperli®) edenneessä tai uusiutuneessa MMR-puutteisessa (mismatch repair deficient) kohdunrunkosyövässä, jossa tauti on progredioinut platinapohjaisen solunsalpaajahoidon aikana tai sen jälkeen | Yes |
| 11/2021 | OYS | Syväaivostimulaatio (DBS) vaikeahoitoisen epilepsian hoidossa | Yes |
| 10/2021 | HUS | Avelumabi (Bavencio®) uroteelisyövässä ylläpitohoitona ensimmäisessä hoitolinjassa sytostaattihoidon jälkeen | Yes |
| 10/2021 | KYS | Nivolumabi (Opdivo®) ja ipilimumabi (Yervoy®) yhdistelmähoitona paikallisesti edenneen ja metastaattisen melanooman hoidossa | Yes |
| 9/2021 | HUS | Tekoälypohjainen sädehoidon normaalikudosten autosegmentointi | Yes |
| 9/2021 | HUS | PET-MK, metabolinen kuvantaminen yhdistettynä ei-ionisoivaan anatomiseen magneettikuvaukseen | Yes |
| 8/2021 | HUS | Korkeaintensiteettinen ultraääni (HIFU) paikallisen ja paikallisesti uusiutuneen eturauhassyövän hoitona | Yes |
| 8/2021 | HUS | Edenneen munuaissyövän ensilinjan lääkehoidot: Nivolumabin ja ipilimumabin ja nivolumabin ja kabotsantinibin yhdistelmähoidot | Yes |
| 8/2021 | HUS | Nivolumabin ja ipilimumabin yhdistelmähoito malignin pleuramesoteliooman ensilinjan hoidossa | Yes |
| 6/2021 | HUS | Pembrolitsumabi (Keytruda®) metastasoineen paksusuolisyövän ensilinjan hoitoon aikuispotilailla, joiden syöpään liittyy mikrosatelliitti-instabiliteetti (MSI-H) tai puutteellinen DNA:n kahdentumisvirheiden korjausmekanismi (dMMR) | Yes |
| 6/2021 | TAYS | Nivolumabi (Opdivo®) levinneen munuaissyövän 1. linjan hoitona yhdessä kabotsantinibin kanssa | Yes |
| 6/2021 | TAYS | Nivolumabi (Opdivo®) levinneessä ruokatorven levyepiteelisyövässä platina-fluoro-yhdistelmän jälkeen, ECOG luokka 0-1 | Yes |
| 6/2021 | TAYS | Inklisiraani (Leqvio®) vaikeassa hyperkolesterolemiassa | Yes |
| 5/2021 | TAYS | Kertakäyttöskooppi (single-use endoscope) | Yes |
| 5/2021 | HUS | Kritsanlitsumabi (Adakveo®) toistuvien vaso-okklusiivisten kriisien ennaltaehkäisyyn sirppisolutautia sairastavilla 16 vuotta täyttäneillä potilailla | Yes |
| 5/2021 | HUS | Atetsolitsumabin (Tecentriq®) ja bevasitsumabin yhdistelmähoito edennyttä tai leikkauksella poistettavaksi soveltumatonta hepatosellulaarista karsinoomaa (HCC) sairastavien aikuispotilaiden hoitoon, kun potilas ei ole aiemmin saanut systeemistä hoitoa | Yes |
| 4/2021 | HUS | Trikuspidaaliläppävuodon korjaamisen katetritoimenpiteet: Cardioband ja Tricento | Yes |
| 4/2021 | HUS | Olympus Powerspiral -enteroskooppi | Yes |
| 4/2021 | HUS | Portapaineen ja maksalaskimon paine-eron mittaaminen endoskooppiseen ultraäänitekniikkaan perustuvalla menetelmällä | Yes |
| 4/2021 | HUS | Tahdistinlaitteiden etäseurannan yhteen kokoava järjestelmä | Yes |
| 3/2021 | TAYS | Mogamulimutsumabi (Poteligeo®) mycosis fungoideksen tai Sézaryn oireyhtymän hoito, kun potilas on saanut vähintään yhtä aiempaa systeemistä hoitoa | Yes |
| 3/2021 | TAYS | Pembrolitsumabi (Keytruda®) metastasoituneen kolorektaalisyövän ensilinjan hoidossa | Yes |
| 2/2021 | TAYS | Akupunktio ja psykoosi | Yes |
| 2/2021 | TAYS | Game ready -kylmäkompressiolaite turvotuksen ja kivun hoidossa vammapotilailla | Yes |
| 12/2020 | HUS | Imlifidaasi (Idefirix®) desensitisaatiohoitona voimakkaasti immunisoituneille munuaisensiirtopotilaille | Yes |
| 11/2020 | TYKS | Kanakinumabi (Ilaris®) juveniilin idiopaattisen artriitin hoidossa | Yes |
| 10/2020 | HUS | Ravulitsumabi (Ultromiris®) atyyppisen hemolyyttis-ureemisen syndrooman (aHUS) hoidossa | Yes |
| 10/2020 | HUS | Atetsolitsumabi (Tecentriq®) paikallisesti edenneen tai metastasoituneen uroteelikarsinooman ensilinjan hoidossa, jos potilaalle ei sovi sisplatiini | Yes |
| 7/2020 | OYS | Laboratoriotutkimuksen suPAR käyttö kuoleman riskin ennustamisessa | Yes |
| 5/2020 | HUS | Trastutsumabiemtansiinin (Kadcyla®) HER2-positiivista rintasyöpää sairastavien potilaiden neoadjuvanttihoidon jälkeen liitännäishoitona, jos potilas ei ole saanut täydellistä hoitovastetta neoadjuvanttihoidolla | Yes |
| 5/2020 | TAYS | Dupilumabi (Dupixent®) hankalan kroonisen polypoottisen sinuiitin hoidossa | Yes |
| 3/2020 | OYS | Matalatehoinen sähkökenttähoito (Tumor Treating Fields, TTFields; Optune®) glioblastooman hoidossa | Yes |
| 3/2020 | TAYS | Sapropteriinihydrokloridi (Kuvan®) harvinaista synnynnäistä aineenvaihduntasairautta (PTPS-puutos) sairastavien lasten hoidossa | Yes |
| 1/2020 | HUS | Pembrolitsumabi (Keytruda®) uusiutuneen tai metastaattisen pään ja kaulan alueen syövän ensimmäisen linjan hoidossa monoterapiana tai sytostaattikombinaatiossa | Yes |
| 11/2019 | TAYS | Gemtutsumabi-otsogamisiini (Mylotarg®) solunsalpaajahoitoon yhdistettynä pienen riskin (CBF) akuutin myelooisen leukemian (AML) hoidossa | Yes |
| 9/2019 | HUS | Daunorubisiini + sytarabiini (CPX-351, Vyxeos®) induktio- ja konsolidaatiohoitona aikaisempaan hoitoon liittyvässä akuutissa myelooisessa leukemiassa tai sekundaarisessa remissiossa (MDS/KMML jälkeinen AML) | Yes |
| 9/2019 | TAYS | Bedakiliini (Sirturo®) ensilinjan lääkkeenä monilääkeresistantin tuberkuloosin (MDR-TB) lääkeyhdistelmää muodostettaessa | Yes |
| 9/2019 | HUS | Kaplasitsumabi (Cablivi®) hankitun tromboottisen trombosytopeenisen purppuran (aTTP) akuuttivaiheen hoidossa | Yes |
| 8/2019 | OYS | Ravulitsumabi (Ultomiris®) paroksysmaalisen nokturnaalisen hemoglobinurian (PNH) hoidossa | Yes |
| 6/2019 | HUS | Pembrolitsumabi (Keytruda®) yhdistettynä solunsalpaajakombinaation kanssa metastaattisen levyepiteeliperäisen ei-pienisouluisen keuhkosyövän ensilinjan hoidossa, kun tuumorin PD-L1-ligandin ilmentymä on alle 50 % | Yes |
| 3/2019 | HUS | Patisiraani (Onpattro®) perinnöllisen transtyretiinivälitteisen amyloidoosin (hATTR) hoidossa | Yes |
| 2/2019 | OYS | Midostauriini (Rydapt®) FLT3-mutaatiopositiivisten akuuttia myelooista leukemiaa (AML) sairastavien potilaiden hoidossa (sairaalakäyttö). | Yes |
| 2/2019 | OYS | Lämpimien (+38 astetta) I.V.-nesteiden käytön tarpeellisuus ensihoidossa ja niiden vaatiman välineistön käyttö ambulanssissa | Yes |
| 2/2019 | TAYS | Sepsis ja sytokiinifiltteri (CytoSorb®) | Yes |
| 1/2019 | HUS | Pembrolitsumabi (Keytruda®) yhdistelmänä pemetreksedin ja platinasolunsalpaajahoidon kanssa metastoituneen, ei-levyepiteeliperäisen ei-pienisoluisen keuhkosyövän ensilinjan hoidossa | Yes |
| 1/2019 | HUS | Talimogene laherparepvec (TVEC, T-VEC, Imlygic®) edenneen melanooman 1. tai myöhemmän linjan hoidossa asteiden IIIB/C, IVM1a melanoomapotilailla | Yes |
| 12/2018 | TAYS | Aflibersepti (Eylea®) kostean silmänpohjan ikärappeuman hoidossa | Yes |
| 12/2018 | TAYS | Ledipasviiri/sofosbuviiri (Harvoni®) kroonisen C-hepatiitin hoidossa 12 vuotta täyttäneillä potilailla | Yes |
| 12/2018 | OYS | Ramusirumabi (Cyramza®) edenneen mahasyövän ja ruokatorvi-mahalaukkurajan adenokarsinooman toisen linjan hoidossa | Yes |
| 11/2018 | HUS | Avelumabi (Bavencio®) metastasoineen merkelinsolusyövän (MCC) hoidossa aikuispotilailla | Yes |
| 9/2018 | HUS | Darvadstroseli (Alofisel®) Crohnin taudin perianaalisten fisteleiden hoidossa | Yes |
| 9/2018 | HUS | Nivolumabi (Opdivo®) uusiutuneen tai metastaattisen pään ja kaulan alueen toisen tai myöhemmän linjan syövän hoidossa platinapohjaisen standardihoidon jälkeen | Yes |
| 9/2018 | HUS | Nivolumabi (Opdivo®) asteiden IIIB-D ja IV melanooman liitännäishoitona | Yes |
| 8/2018 | OYS | Nab-paklitakseli (Abraxane®) paklitakselista tai dosetakselista allergisen infuusioreaktion saaneiden gynekologisten syöpäpotilaiden hoidossa | Yes |
| 9/2018 | HUS | Takajuurisolmukkeen stimulaatio (Dorsal root ganglion stimulation, DRGS) kroonisen kivun hoidossa | Yes |